Target intelligence / Profile preview

Synaptotagmin-8 (SYT8)

Target
SYT8
Molecular classification
Membrane protein, C2 domain-containing protein, Exocytosis regulator
01

Overview

Synaptotagmin-8 (SYT8) is a membrane protein belonging to the synaptotagmin family, characterized by C2 domains and involvement in the regulation of exocytosis in both neuronal and non-neuronal tissues[5][2][4]. While synaptotagmins generally function as Ca²⁺ sensors, SYT8 does not display canonical Ca²⁺-dependent activity but is crucial in coupling insulin gene activity to secretion in pancreatic islet cells[3][2]. SYT8 modulates secretory granule trafficking and release, significantly impacting insulin exocytosis and hormone secretion[4][3]. Its gene expression is controlled by long-range chromatin interactions with the insulin gene promoter in a glucose-dependent manner[2][3]. Beyond endocrine functions, increased SYT8 expression has been identified in several cancers (notably pancreatic and gastric), where it promotes tumor growth, migration, and metastasis through interactions with the SIRT1, ERRα, and TNNI2 signaling axis[1][2]. These features make SYT8 a molecular effector in secretory pathways and a candidate biomarker or therapeutic target in oncology[1][2].

Other names
Synaptotagmin-8SYT8SytVIIIDKFZp434K0322Synaptotagmin VIIIsynaptotagmin-8synaptotagmin VIIIsytVIII
02

Mechanism of action

Modulation of exocytosis and secretion via protein–protein interactions in the secretory machinery, especially through non-Ca²⁺-dependent mechanisms

03

Biological functions

Regulation of hormone secretion (including insulin)Regulation of neurotransmissionRegulation of secretory vesicle exocytosisModulation of exocytosis in non-neuronal tissues
04

Disease associations

Cancer (notably pancreatic cancer, also implicated in gastric cancer)Potential biomarker for cancer progression and metastasis
05

Safety considerations

Overexpression may promote tumor progression and metastasis, suggesting oncogenic potential
06

Biomarkers

Upregulation in pancreatic and gastric cancer tissues as a prognostic or diagnostic biomarker

Beyond the preview

Go deeper on Synaptotagmin-8 (SYT8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptotagmin-8 (SYT8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call